AS 603
Alternative Names: AS-603; S-603Latest Information Update: 12 Apr 2024
At a glance
- Originator Amyloid Solution
- Class Antidementias
- Mechanism of Action Amyloid beta-protein modulators; Tau protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 12 Apr 2024 Preclinical trials in Alzheimer's disease in South Korea (unspecified route) (Amyloid solution pipeline, April 2024
- 28 Nov 2022 Early research in Alzheimer's disease in South Korea (unspecified route), before November 2022 (Amyloid solution pipeline, November 2022)